Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate.

King CD, Rios GR, Assouline JA, Tephly TR.

Arch Biochem Biophys. 1999 May 1;365(1):156-62.

PMID:
10222050
2.

Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.

Chau N, Elliot DJ, Lewis BC, Burns K, Johnston MR, Mackenzie PI, Miners JO.

J Pharmacol Exp Ther. 2014 Apr;349(1):126-37. doi: 10.1124/jpet.113.212258. Epub 2014 Jan 23.

PMID:
24459244
3.

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO.

Drug Metab Dispos. 2003 Sep;31(9):1086-9. Erratum in: Drug Metab Dispos. 2003 Dec;31(12):1541.

PMID:
12920162
4.
5.

Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ.

Drug Metab Dispos. 2001 May;29(5):686-92.

PMID:
11302935
6.

Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.

Benoit-Biancamano MO, Connelly J, Villeneuve L, Caron P, Guillemette C.

Drug Metab Dispos. 2009 Feb;37(2):322-9. doi: 10.1124/dmd.108.023101. Epub 2008 Oct 29.

PMID:
18971318
8.

Simultaneous expression of guinea pig UDP-glucuronosyltransferase 2B21 and 2B22 in COS-7 cells enhances UDP-glucuronosyltransferase 2B21-catalyzed morphine-6-glucuronide formation.

Ishii Y, Miyoshi A, Watanabe R, Tsuruda K, Tsuda M, Yamaguchi-Nagamatsu Y, Yoshisue K, Tanaka M, Maji D, Ohgiya S, Oguri K.

Mol Pharmacol. 2001 Nov;60(5):1040-8.

PMID:
11641432
9.

Human UDP-glucuronosyltransferase 2B7.

Radominska-Pandya A, Little JM, Czernik PJ.

Curr Drug Metab. 2001 Sep;2(3):283-98.

PMID:
11513331
10.

Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1.

Rios GR, Tephly TR.

Drug Metab Dispos. 2002 Dec;30(12):1364-7.

PMID:
12433804
11.

UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects.

Bock KW, Köhle C.

Methods Enzymol. 2005;400:57-75. Review.

PMID:
16399343
12.

Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes.

Kuehl GE, Bigler J, Potter JD, Lampe JW.

Drug Metab Dispos. 2006 Feb;34(2):199-202. Epub 2005 Oct 28.

PMID:
16258079
13.

A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes.

Rahikainen T, Häkkinen MR, Finel M, Pasanen M, Juvonen RO.

Xenobiotica. 2013 Oct;43(10):853-61. doi: 10.3109/00498254.2013.783724. Epub 2013 Apr 3.

PMID:
23551063
14.

Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.

Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, Wrighton SA.

Pharmacogenetics. 2000 Nov;10(8):727-39.

PMID:
11186135
15.

In vitro morphine metabolism by rat microglia.

Togna AR, Antonilli L, Dovizio M, Salemme A, De Carolis L, Togna GI, Patrignani P, Nencini P.

Neuropharmacology. 2013 Dec;75:391-8. doi: 10.1016/j.neuropharm.2013.08.019. Epub 2013 Aug 27.

PMID:
23988259
16.

Human UGT2B7 catalyzes morphine glucuronidation.

Coffman BL, Rios GR, King CD, Tephly TR.

Drug Metab Dispos. 1997 Jan;25(1):1-4.

PMID:
9010622
17.

Morphine regulation of a novel uridine diphosphate glucuronosyl-transferase in guinea pig pups following in utero exposure.

Smith SA, Nagalla SR, Andrews DP, Olsen GD.

Mol Genet Metab. 1999 Sep;68(1):68-77.

PMID:
10479484
18.

Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7.

Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, Tephly TR.

Toxicol Sci. 1998 Sep;45(1):52-7.

PMID:
9848110
19.

Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse.

Al Saabi A, Allorge D, Sauvage FL, Tournel G, Gaulier JM, Marquet P, Picard N.

Drug Metab Dispos. 2013 Mar;41(3):568-74. doi: 10.1124/dmd.112.047878. Epub 2012 Dec 10.

PMID:
23230132
20.

Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6.

Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, Hirvonen J, Goldman A, Finel M.

Pharmacogenet Genomics. 2007 Feb;17(2):115-26.

PMID:
17301691

Supplemental Content

Support Center